01—Abstract
Summary
Summary of the 10-Q filed August 5, 2026. Cited figures are marked; the original filing is the authoritative source.
Royalty Pharma plc (RPRX) reported second-quarter 2026 consolidated net income of $81.5 milliona, down from $92.6 million a year earlier, while net income attributable to Royalty Pharma plc fell to $17.9 million from $32.2 million.
For the first six months of 2026, net income attributable to Royalty Pharma plc rose to $312.6 millionb from $271.5 million, and diluted EPS was $0.71 versus $0.63. Total income and other revenues grew to $674.1 million in the quarter from $578.7 million, driven by higher income from financial royalty assets, which was $638.0 million versus $550.4 million. Operating income declined to $133.1 million from $209.8 million, mainly because of a $268.2 million provision for changes in expected cash flows, largely tied to Adstiladrin, compared with a $203.9 million provision benefit in the prior-year quarter.
Cash generation remained strong. Net cash provided by operating activities for the first six months of 2026 was $1.45 billionc, up from $960.1 million, and Portfolio Cash Flow was $1.46 billion. The company invested $876.7 million in royalties, milestones and other contractual receipts in the first half.
Cash and cash equivalents were $812.0 milliond at June 30, 2026. Total debt principal was $9.2 billion, and the company entered a new $1.8 billion unsecured revolving credit facility on May 22, 2026, which matures in 2031. Share-based compensation rose sharply after the May 2025 Internalization, reaching $107.4 million in the quarter.
Subsequent to quarter end, the company acquired a royalty interest in AstraZeneca's cliramitug from Neurimmune AG for up to $425 million, including a $125 million upfront payment. The filing also notes an ongoing dispute with Vertex over royalties on Alyftrek, under which the company has not received the full royalty amounts it believes it is contractually entitled to.
02—Key points
Key Highlights
- Net income attributable to Royalty Pharma plc was $17.9 million in Q2 2026 versus $32.2 million in Q2 2025; diluted EPS was $0.04 versus $0.07.
- For the first six months of 2026, net income attributable to Royalty Pharma plc was $312.6 million, up from $271.5 million, and diluted EPS was $0.71 versus $0.63.
- Income from financial royalty assets rose 15.9% to $638.0 million in Q2 2026, driven by Tremfya, the cystic fibrosis franchise and Imdelltra.
- Q2 2026 included a $268.2 million provision for changes in expected cash flows, primarily related to Adstiladrin, compared with a $203.9 million provision benefit in Q2 2025.
- Net cash provided by operating activities was $1.45 billion for the first six months of 2026, up from $960.1 million, and the company invested $876.7 million in royalties and contractual receipts.
- A new $1.8 billion unsecured revolving credit facility was entered into on May 22, 2026, maturing May 22, 2031, with no borrowings outstanding at June 30, 2026.
- In July 2026, the company acquired a royalty interest in AstraZeneca's cliramitug for up to $425 million, including a $125 million upfront payment.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2026filed August 5, 2026Financial Statements
Q2 FY2026 against Q2 FY2025
| Line item | Q2 FY2026Q2 FY2025 | Change |
|---|---|---|
| Revenue | $674.14M$578.66M | +16.5% |
| R&D Expenses | $97.85M$300.50M | −67.4% |
| Operating Expenses | $541.02M$368.87M | +46.7% |
| Operating Income | $133.12M$209.80M | −36.5% |
| Net Income | $17.88M$32.18M | −44.4% |
| EPS (Basic) | $0.04$0.08 | −50.0% |
| EPS (Diluted) | $0.04$0.07 | −42.9% |
| Shares Outstanding (Basic) | 445.06M423.51M | +5.1% |
| Shares Outstanding (Diluted) | 556.90M562.30M | −1.0% |
05—Questions
Frequently Asked Questions
Why did net income attributable to Royalty Pharma plc decline in the second quarter of 2026?
Operating income fell to $133.1 million from $209.8 million, largely because of a $268.2 million provision for changes in expected cash flows from financial royalty assets, compared with a $203.9 million provision benefit in the prior-year quarter. The provision expense was mainly related to Adstiladrin due to a decline in its sales forecast, partly offset by a Tysabri provision benefit. Net income attributable to non-controlling interests also rose to $63.6 million from $60.5 million.
What drove the growth in revenue and royalty income?
Income from financial royalty assets increased by $87.6 million, or 15.9%, in the second quarter, driven mainly by Tremfya, the cystic fibrosis franchise and $27.6 million of interest income from Imdelltra, which was acquired in the third quarter of 2025. Other royalty income and revenues increased 27.9%, primarily due to Trodelvy sales growth.
How is the company's share-based compensation changing, and why does it matter?
Share-based compensation expense was $107.4 million in the second quarter of 2026 and $229.6 million in the first six months, compared with $91.0 million and $91.7 million in the respective 2025 periods. The increase follows the May 2025 Internalization, which included RP Holdings Class E Interests, Employee EPAs and Employee RSUs. As of June 30, 2026, the company had $570.9 million of unrecognized compensation expense related to Class E Interests and $124.5 million related to Employee EPAs.
What is the status of the company's debt and liquidity?
Total borrowings principal was $9.2 billion as of June 30, 2026, including $8.8 billion of senior unsecured notes and a $380 million term loan that the company repaid in July 2026 at maturity. Cash and cash equivalents were $812.0 million. The company has a $1.8 billion revolving credit facility and a $350.0 million uncommitted credit facility, and the filing states it was in compliance with financial covenants as of June 30, 2026.
What is the dispute with Vertex about?
Beginning in the second quarter of 2025, the company did not receive from Vertex the full amount of royalty receipts on Alyftrek net sales that it believes it is contractually entitled to receive. The company has commenced dispute resolution procedures, and any amounts receivable will be recognized only upon resolution of the matter in its favor.
06—Continue